Clasp Therapeutics is dedicated to advancing the field of immuno-oncology through the development of next-generation T cell engagers (TCEs). These therapeutics empower a patient's T cells to accurately target and eliminate tumor cells, significantly reduced the risk of on-target, off-tumor toxicities commonly associated with other therapies. Founded in 2020, Clasp Therapeutics specializes in addressing challenging cancer types that display prevalent driver mutations by targeting specific mutated protein fragments presented by specialized HLA. Their approach is designed to create an effective immune response by facilitating close interactions between T cells and tumor cells. Headquartered in Cambridge, MA, with additional operations in Rockville, MD, Clasp has cultivated a team-oriented and dynamic environment, recently securing $150 million in funding to support its innovative drug development pipeline.